with a safety profile consistent with Bexsero and Menveo. GSK’s chief scientific officer, Tony Wood, said that the results show the vaccine protects against “the broadest panel of circulating ...

Penmenvy combines the antigenic components of GSK’s approved Bexsero and Menveo meningococcal vaccines to target five common invasive meningococcal disease (IMD)-causing serotypes (A, B, C, W and Y).

1 GSK’s MenABCWY vaccine combines the antigenic components of the Company’s two well-established meningococcal vaccines—Bexsero (Meningococcal Group B Vaccine) and Menveo (Meningococcal [Groups A, C, ...

GSK said Penmenvy, which combines components of its Bexsero and Menveo vaccines, could improve vaccination rates by reducing the number of injections required. It is expected to be available in ...